0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metabolic dysfunction‐associated fatty liver disease (MAFLD) is a complex disease involving alterations in multiple biological processes regulated by the interactions between obesity, genetic background, and environmental factors including the microbiome. To decipher hepatic steatosis (HS) pathogenesis by excluding critical confounding factors including genetic variants and diabetes, 56 heterogenous MAFLD patients are characterized by generating multiomics data including oral and gut metagenomics as well as plasma metabolomics and inflammatory proteomics data. The dysbiosis in the oral and gut microbiome is explored and the host–microbiome interactions based on global metabolic and inflammatory processes are revealed. These multiomics data are integrated using the biological network and HS's key features are identified using multiomics data. HS is finally predicted using these key features and findings are validated in a follow‐up cohort, where 22 subjects with varying degree of HS are characterized.

          Abstract

          A comprehensive study to decipher hepatic steatosis (HS) by generating multiomics data including oral and gut metagenomics as well as plasma metabolomics and inflammatory proteomics data in a well‐characterized metabolic dysfunction‐associated fatty liver disease (MAFLD) cohort.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: not found
          • Article: not found

          The diverse roles of CDCP1 in cancer and metabolism

          H. Wright (2017)
            Bookmark

            Author and article information

            Contributors
            jan.boren@wlab.gu.se
            adilm@scilifelab.se
            Journal
            Adv Sci (Weinh)
            Adv Sci (Weinh)
            10.1002/(ISSN)2198-3844
            ADVS
            Advanced Science
            John Wiley and Sons Inc. (Hoboken )
            2198-3844
            07 February 2022
            April 2022
            : 9
            : 11 ( doiID: 10.1002/advs.v9.11 )
            : 2104373
            Affiliations
            [ 1 ] Department of Gastroenterology and Hepatology School of Medicine Koç University Istanbul 34010 Turkey
            [ 2 ] NIHR Nottingham Biomedical Research Centre Nottingham University Hospitals NHS Trust & University of Nottingham Nottingham NG5 1PB UK
            [ 3 ] Nottingham Digestive Diseases Centre School of Medicine University of Nottingham Nottingham NG7 2UH UK
            [ 4 ] Science for Life Laboratory KTH – Royal Institute of Technology Stockholm SE‐17121 Sweden
            [ 5 ] School of Medicine Koç University Istanbul 34010 Turkey
            [ 6 ] Centre for Host‐Microbiome Interactions Faculty of Dentistry, Oral & Craniofacial Sciences King's College London London SE1 9RT UK
            [ 7 ] Department of Medical Biology Faculty of Medicine Atatürk University Erzurum 25240 Turkey
            [ 8 ] Department of Biology and Biological Engineering Chalmers University of Technology Gothenburg SE‐41296 Sweden
            [ 9 ] Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education School of Pharmaceutical Sciences Zhengzhou University Zhengzhou Henan Province 450001 China
            [ 10 ] Department of Molecular and Clinical Medicine University of Gothenburg and Sahlgrenska University Hospital Gothenburg Gothenburg SE‐41345 Sweden
            [ 11 ]Present address: Laboratory of Cardiovascular Physiology and Tissue Injury and Section on Fibrotic Disorders National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health Rockville MD 20852 USA
            Author notes
            Author information
            https://orcid.org/0000-0002-4254-6090
            Article
            ADVS3596
            10.1002/advs.202104373
            9008426
            35128832
            f1790e94-ebbc-49d6-814a-71b7f0d61e71
            © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH

            This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

            History
            : 22 December 2021
            : 01 October 2021
            Page count
            Figures: 9, Tables: 1, Pages: 20, Words: 12201
            Funding
            Funded by: Knut and Alice Wallenberg Foundation , doi 10.13039/501100004063;
            Funded by: ScandiBio Therapeutics AB, Sweden
            Funded by: PoLiMeR Innovative Training Network
            Funded by: Marie Skłodowska‐Curie
            Award ID: 812616
            Funded by: European Union's Horizon 2020
            Funded by: Uppsala Multidisciplinary Center for Advanced Computational Science , doi 10.13039/501100015701;
            Award ID: sens2019031
            Categories
            Research Article
            Research Articles
            Custom metadata
            2.0
            April 14, 2022
            Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.4 mode:remove_FC converted:14.04.2022

            gut and oral metagenomics,metabolic dysfunction‐associated fatty liver disease,metabolomics,multiomics analysis,proteomics,systems biology,systems medicine

            Comments

            Comment on this article